Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Preliminary Verifying Study About Safety and Efficacy of Maintenance DCVAC/OvCa After First-line Chemotherapy Added to Standard of Care in Patients With Newly Diagnosed FIGO III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.

NCT04834544 is registered in ClinicalTrials.gov with Peking University Third Hospital as lead sponsor.

NCT NCT04834544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04834544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Preliminary Verifying Study About Safety and Efficacy of Maintenance DCVAC/OvCa After First-line Chemotherapy Added to Standard of Care in Patients With Newly Diagnosed FIGO III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma.
Lead sponsor
Peking University Third Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
April 19, 2021
Completion date
April 20, 2027
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epithelial ovarian carcinoma, fallopian tube carcinoma, primary peritoneal carcinoma